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Healthcare associated infections (HCAIs) occur in all parts
of the healthcare system. The change in nomenclature from
nosocomial or hospital-acquired infections is important
because the best methods to prevent HCAIs are those
directed at many different levels. As the UK Department of
Health Winning Ways report noted: ‘there is seldom any
quick fix’.1
HCAIs include urinary and respiratory tract infections,
bacteraemias and intravascular catheter infections, surgical
site infections (SSIs) and Clostridium difficile emergence. A
contributory factor to the increase in HCAIs has been the
mis-use of antibiotics in healthcare and food production
which has driven: (i) the proliferation of extended spectrum
β-lactamases and resistance related to urinary infections;
(ii) the emergence of glycopeptide-resistant enterococci
and ventilator-associated pneumonias; and (iii) multiple
drug resistant, coagulase-negative staphylococci on vascu-
lar catheters and joint prostheses. Meticillin resistant
Staphylococcus aureus (MRSA) bacteraemia is declining in
the UK but resistance underscores the need for antibiotic
stewardship, particularly of newer broad-spectrum agents.
The UK Department of Health advocates that antibiotics
should be used for treatable infections, the choice being
governed by information about antibiotic resistance pat-
terns and sensitivities.1 Antibiotics should be used for pro-
phylaxis of infection only when there is proven benefit,
preferably with narrow spectrum antibiotics over a pre-
scribed period at the correct dose. Alternatives to antibiotic
therapy, such as a greater use of antiseptics or novel antibac-
terial sutures, are attractive prospects for surgical practice.
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ABSTRACT
This report is based on a Hygienist Panel Meeting held at St Anne’s Manor, Wokingham on 24–25 June 2009. The panel
agreed that greater use should be made of antiseptics to reduce reliance on antibiotics with their associated risk of antibiotic
resistance. When choosing an antiseptic for clinical use, the Biocompatibility Index, which considers both the microbiocidal
activity and any cytotoxic effects of an antiseptic agent, was considered to be a useful tool. The need for longer and more pro-
active post-discharge surveillance of surgical patients was also agreed to be a priority, especially given the current growth of
day-case surgery. The introduction of surgical safety checklists, such as the World Health Organization’s Safe Surgery Saves
Lives initiative, is a useful contribution to improving safety and prevention of SSIs and should be used universally. Considering
sutures as ‘implants’, with a hard or non-shedding surface to which micro-organisms can form biofilm and cause surgical site
infections, was felt to be a useful concept.
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Surgical site infection
SSIs occur frequently and their prevention and treatment, espe-
cially those involving prosthetics, is challenging. SSIs comprise
up to 20% of all HCAIs in the UK. At least 5% of patients under-
going surgery develop an SSI, which has an effect on quality of
life and is a financial burden to healthcare providers.2 This is
lamentable given that the majority of SSIs are preventable.
Furthermore, whilst SSIs after clean-wound surgery have been
reported as being as low as 1.4%,3 this is an underestimation. If
a trained and blinded observer is involved, using close and pro-
longed post-discharge surveillance (PDS) to at least 30 days
postoperatively (and a year after major joint replacement
surgery), with agreed definitions, the SSI rate is much high-
er. Surgical wounds are categorised as ‘clean’,
‘clean–contaminated’, ‘contaminated’ or ‘dirty’. Scoring sys-
tems, such as the ASEPSIS score4 (Additional treatment, Serous
discharge, Erythema, Purulent exudates, Separation of deep tis-
sues, Isolation of bacteria and Stay duration as in-patient) allow
further evaluation with interval data. Other scores such as
SENIC (Study on the Efficacy of Nosocomial Infection Control)
and NNIS risk index can identify patients at high risk of SSI.5
Prevention
Several guidelines exist for prevention of surgical site infec-
tion, including those produced by the UK National Institute
for Health and Clinical Excellence (NICE).
Pre-operative phase
1. Hair removal should not be undertaken to reduce the
risk of SSI.
2. If hair has to be removed, use electric clippers with a
single-use head on the day of surgery. Razors used for
hair removal increase the risk of SSI.
3. Give antibiotic prophylaxis before clean prosthetic sur-
gery, clean-contaminated surgery and contaminated
surgery but not routinely for clean, non-prosthetic,
uncomplicated surgery using local antibiotic formula-
ries which consider potential adverse effects.
4. Consider a single dose intravenously on starting anaesthe-
sia but give prophylaxis earlier when a tourniquet is used.
Intra-operative phase
1. Prepare the skin before the incision using antiseptics
such as povidone iodine or chlorhexidine.
2. Cover surgical incisions with an interactive dressing.
Postoperative phase
1. Refer to a tissue viability nurse, or equivalent, for advice
on appropriate dressings for surgical wounds which are
healing by secondary intention after an infection.
Patient homeostasis
Tissues heal well with optimal oxygenation, perfusion and
body temperature. Avoiding hypothermia is a component of
care bundles and may help to reduce the overuse of antibi-
otics.6 In hernia surgery, postoperative pain scores may be
lowered after pre-warming with lower ASEPSIS wound
scores.7 A meta-analysis8 concluded that hypothermia, aver-
aging only 1.5ºC less than normal, results in adverse out-
comes adding between US$2,500–7,000 for each surgical
patient. Avoidance of hypothermia is also associated with
fewer adverse outcomes and shorter hospital stay.
There are many causes of hypothermia (< 36ºC) in the cool,
dry operating theatre environment, including cold intravenous
fluids and anaesthetic gases, and vasodilatation (or inhibited
vasoconstriction) which lead to increased BMR and oxygen
requirements and poor oxygen delivery. The physiological com-
plications of hypothermia include shivering, increasing oxygen
demand, a shift in the oxygen dissociation curve, acidosis, rela-
tive organ ischaemia andmyocardial infarction. Higher inspired
oxygen concentrations in the peri-operative period may reduce
SSI rates when compared with lower oxygen concentration.9
However, peri-operative tissue oxygen tension in obese surgical
patients, evenwith supplemented oxygen, can fall to levels asso-
ciated with an increased infection risk.10
Checklist approach
An initiative to improve the safety of surgery has been the
introduction of surgical safety checklists.11 Deaths and compli-
cations were reduced bymore than a third in a year-long study
using the World Health Organization (WHO) Safe Surgery
Saves Lives initiative, which involved hospitals in eight cities
around the world. The checklist requires onlyminutes to com-
plete: before anaesthesia; before skin incision; and before the
patient is removed from the operating room. Safe delivery of
anaesthesia, appropriate preventive measures and reduction
of infection and effective teamwork are ensured.
Implants, bacterial adhesion and biofilms: their
roles in surgical site infection
Around half of the two million cases of HCAIs which occur
annually in the US are associated with in-dwelling devices.
Infections associated with permanent implants are more like-
ly to occur and are difficult to manage because they require
long courses of antibiotics and repeated surgical procedures.12
Surgical sutures may also be considered as implants and,
when bacteria contaminate tissues, sutures increase the viru-
lence of organisms responsible for SSIs. Coating implants and
sutures with a wide-spectrum antibacterial agent, such as tri-
closan, has the potential to reduce SSIs, particularly after
prosthetic and contaminated surgery, and be an adjunct to
antibiotics and lessen their overuse.
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Implants are used in orthopaedics; as cardiovascu-
lar/vascular stents, pacemakers, grafts and shunts; and in
cosmetic and dental surgery. Sutures, like most other
implants, have a non-shedding surface to which bacteria
can adhere, form biofilms and potentiate SSIs. The adher-
ence of bacteria to various sutures has been investigated,13
and variations in adherence-affinity correlated with infec-
tion. Another study14 examined the physical and chemical
properties of suture materials on the adherence of S. aureus
and Escherichia coli. Ten suture materials were tested
(including catgut, Dexon, Vicryl, PolyDioaxanone Suture
and Prolene); of the absorbable sutures, PDS exhibited the
lowest adherence-affinity whereas Dexon sutures had the
highest. Suture-related keratitis, following penetrating ker-
atoplasty, has been reported15 triggered by a suture allowing
Corynebacterium macginleyi to migrate into the cornea and
form a biofilm.
Biofilms: are they significant in SSI and how can
they be managed?
Biofilms are ubiquitous and form whenever micro-organ-
isms (bacteria, yeasts, algae, fungi, or protozoa) attach to
surfaces. Once attached, planktonic (free-living) bacteria
undergo a phenotypic change and, within minutes, deposit
‘slime’: extracellular polymeric material (EPS) or biofilm
matrix. Implants have non-shedding surfaces which can be
colonised by skin or other bacteria during surgery, to form
a biofilm. Of all human infections, at least 60% are thought
to involve biofilms.
The recognition that biofilms are the dominant mode of
microbial growth, and that the majority of bacteria exist in
biofilms, is relatively recent. Once established, in the envi-
ronment or in infections, biofilm bacteria are difficult to
treat because, shielded within the matrix, they are less sus-
ceptible to antibiotics and antiseptics. This recalcitrance is
not reflected by laboratory susceptibility tests and a bacteri-
um shown to be susceptible to antibiotics may be impossi-
ble to treat in a biofilm. Reasons for the reduced susceptibil-
ity of biofilm-embedded organisms, compared with plank-
tonic counterparts, includes: (i) heterogeneity of growth
rates; (ii) cells being in a stationary physiological phase,
present as recalcitrant ‘persister’ cells or able to degrade
antimicrobials; and (iii) reduced rates of penetration of the
biofilm by antibiotics.16 Biofilms can also shield their constituent
micro-organisms from the body’s immune system.17
Biofilms, implants and infection
Intravascular catheters and urinary catheters are the two
most common causes of acquired bacteraemia. Biofilm for-
mation on the surfaces of in-dwelling catheters is central to
the pathogenesis of infection.18 Biofilms have also been
implicated in suture-related infection. Post-traumatic
endophthalmitis, unresponsive to systemic, intra-ocular
and topical antibiotic therapy has been described with
slime-producing Staphylococcus epidermidis revealed on
sutures by confocal microscopy. The planktonic form of the
isolate was susceptible in vitro but in biofilm was resistant.19
Preventative strategies
Once a biofilm infection is established on an implant, it usu-
ally needs removal and antibiotic treatment. Preventative
strategies include prophylactic antibiotics before the
biofilm can form, or ‘intelligent’ surfaces that prevent
colonisation or have antimicrobial properties. Potential
antiseptics for coating surfaces include chlorhexidine, poly-
hexamethylene biguanide (PHMB), octenidine and tri-
closan. Compared with antibiotics, which generally have
single pharmacological targets which select for resistance,
antiseptics have several or multiple targets and true ‘resis-
tance’ is rare. Antimicrobial-impregnated implants, which
prevent bacterial adhesion and biofilm formation, can avoid
long-term, ineffective, systemic antibiotics, reduce the risk
of microbial resistance generation and need for implant
removal.
Wound antisepsis and antiseptic sutures: antisep-
tics instead of antibiotics?
Antiseptics are topical antimicrobials which destroy or
inhibit growth of micro-organisms in or on living tissue.
Their use to prevent SSIs has shifted back and forth, being
negative after the high toxicity of Lister’s carbolic wound
spray and the toxic side effects of other early antiseptics
such as organic mercury compounds, dyes, sulphonamides,
nitrofuranes, and quinolinols. The introduction of penicillin
also down-played antiseptics but their current renaissance
probably relates to increasing antibiotic resistance and new,
better tolerated antiseptics.
Tolerability
Ideally, antiseptics should have a rapid, potent and broad
microbiocidal spectrum with long-lasting effects and no
risk of developing antimicrobial resistance. They should be
biocompatible with medical products, not impair healing
processes and be well tolerated in wounds with no toxicity
or systemic absorption. The old surgical aphorism ‘do not
apply anything to a wound that you would not put in your
eye’ remains pertinent. Antiseptics should be not applied if
absorption risks systemic side effects; the choice should be
a balance between risk of damage by infection or toxicity.
The Biocompatibility Index (BI) which considers microbio-
cidal activity and cytotoxic effects can inform this choice.20
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Octenidine
Octenidine has a BI > 1, is rapidly effective, active against
biofilms, not absorbed, has no association with resistance,
does not interfere with wound healing and has no allergic
or toxic risks. Phagocytosis and PDGF may be up-regulated,
but it is toxic to some tissues.21 However, after 3 weeks of
treatment, octenidine eradicated S. aureus, S. epidermidis,
and Proteus mirabilis in neoplastic ulcers.22
Polihexanide
Polihexanide has a BI > 1 and is also active against biofilms,23
is not absorbed and has no allergic or toxic risks. Wound heal-
ing is stimulated but angiogenesis may be delayed.
Polihexanide is suitable for second-degree burns because, in
addition to its antiseptic and debriding action, it does not inhib-
it epithelialisation.24,25
PVP-iodine
PVP-iodine has a BI < 1, is microbiocidal, sporicidal and par-
tially virucidal. It inhibits inflammatory mediators in vitro.
PVP-iodine is absorbed with a risk of sensitisation, is cyto-
toxic, and may be incompatible for peritoneal lavage.
The role of antiseptic impregnated sutures for
prevention of SSI
Implanted foreign materials, including sutures, increase
the risk of SSI.26,27 Sutures in contaminated tissues may
enable micro-organisms to penetrate deeper28 and the
inoculum size of micro-organisms needed to cause an SSI is
105-times lower when foreign material is present.29 Biofilms
around a suture may protect micro-organisms from host
defence mechanisms.30,31 There have been trials of sutures
containing cephalosporins32 and neomycin-impregnated
silk and Dacron implanted into tissues contaminated with S.
aureus, E. coli, P. mirabilis, or Pseudomonas aeruginosa
reduced bacterial numbers.33 Antiseptics have also attracted
interest for incorporation into sutures but iodine products
have not been utilised because of their cytoxicity.34
Triclosan-coated poliglecaprone (Monocryl Plus) has
been evaluated to inhibit bacterial colonization by E. coli
and S. aureus in the mouse and guinea pig.35 After 48 h, the
triclosan-coated suture produced a 3.4-log reduction in S.
aureus and a 2-log reduction in E. coli compared with con-
trol. Another in vivo study showed that triclosan-coated
suture inhibited bacterial colonisation with a 20-mm pro-
tective zone, effective against S. aureus and S. epidermidis,
which was effective for 5–7 days.36 The efficacy of PDS, with
and without triclosan impregnation, was evaluated against
S. aureus, S. epidermidis, Klebsiella pneumoniae, and E. coli
in vitro and in vivo.37 PDS with triclosan demonstrated anti-
bacterial activity which was maintained until the sutures
dissolved.
Potential risks of triclosan-coated devices and
implants
A review of 30 years of triclosan use showed there was no
risk of resistance38 and a toxicology database found no car-
cinogenic potential or genotoxicity.39 There was no evi-
dence of skin sensitisation and pharmacokinetic studies
have shown that triclosan is rapidly absorbed, well distrib-
uted, metabolised in the liver, and excreted by the kidneys.
No association between triclosan and antibiotic resistance
and the susceptibility of bacteria isolated in the community
has been found.40
Antimicrobial sutures: what are the benefits?
The patent application for antimicrobial sutures describes a
multifilament suture with an antimicrobial coating on at
least part of the surface.41 These sutures offer advantages,
including less SSIs with reductions in healthcare costs and
improved quality of life for patients.
Triclosan-coated polyglactin (Vicryl Plus) sutures inhibited in
vitro growth of S. aureus, including MRSA, and S. epidermidis,
which did not diminish for up to 7 days.42 In culture media, the
bacteria-free zone surrounding knotted sutures had a volume of
14–18 cm3 with zones of inhibition persisting after 5–10 passes
through tissue. Cultures of S. aureus, MRSA, S. epidermidis
(biofilm-positive) and E. coli were inoculated in another study
with triclosan-coated andnon-coatedpolyglactin and reductions
in bacterial adherence were observed with antibacterial activity
persisting for at least 96 h.43
A study of breast-reduction surgery found no antimicrobial
effect of triclosan-coated sutures.44 However, a high number of
patients developedwound dehiscence and thereweremethod-
ological inconsistencies. In another clinical study, the intra-
operative handling and wound healing characteristics of tri-
closan-coated polyglactin sutures was addressed in paediatric
surgery.45 The primary end-point was the surgeon’s assess-
ment of intra-operative handling, including: (i) ease of passage
through tissue; (ii) first-throw knot holding; (iii) knot tie-down
smoothness; (iv) knot security; and (v) suture fraying. The tri-
closan-coated sutures received more ‘excellent’ scores (71%
vs 59%; not significant). In a study of post-appendicectomy
SSIs in children, conventional treatment was compared with
the use of triclosan-coated sutures or gentamicin-impregnated
sponges, inserted prior to wound closure.46 The antimicrobial
sutures and sponges significantly reduced SSIs.
In an animal model of prosthetic infection, triclosan-coated
sutures reduced the number of positive cultures after surgery
by two-thirds, compared with a braided suture.47 In a clinical
prosthetic study, which evaluated the incidence of CSF shunt
infections following use of triclosan-coated or conventional
sutures, the infection rate was significantly reduced in the tri-
closan-coated suture group (4.3% vs 21%).48
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A clinical study compared triclosan-coated suture with
standard PDS after more than 2000 mid-line laparotomies and
found that the antimicrobial-coated suture significantly
decreased the number of SSIs (4.9% vs 10.8%).49 The econom-
ic implication of using triclosan-coated sutures for the reduc-
tion of sternal wound infections has been studied in 479
patients undergoing cardiac surgery. Of these, 103 patients
were closed with triclosan-coated sutures and the remaining
376 were closed with non-coated sutures. Twenty-four
patients, all of whom were closed with conventional suture
material, had superficial or deep sternal wound infection at an
estimated cost per patient of US$11,200.50
A recent analysis51 of the cost of SSI in patients undergo-
ing major surgery in a tertiary hospital found an SSI inci-
dence of 9%. The hospital stays of patients with SSIs were
14 days longer than those without an SSI, with additional
hospital costs of US$10,232 per patient (US$97,433 includ-
ing indirect social costs). A simple, cost-effectiveness analy-
sis based on this article is shown in Table 1 (column 2). A
small hospital performing 20,000 surgical procedures annu-
ally with an infection rate of 5% would have 1000 SSIs.
Assuming an SSI reduction using triclosan-coated sutures of
only 10%, use of such a suture, based on current costs,
would avoid 100 SSIs yielding a cost saving of €976,000. A
sensitivity analysis can also be performed when the SSI rate
using triclosan-coated sutures is reduced by only 1%; this
still offers a net benefit of €76,000. After procedures which
have a higher SSI rate the benefits could be even greater.
Conclusions of the panel meeting
The panel agreed that greater use should bemade of antiseptics
to reduce reliance on antibiotics with their associated risk of
antibiotic resistance. When choosing an antiseptic for clinical
use, theBiocompatibility Index,which considers both themicro-
biocidal activity and any cytotoxic effects of an antiseptic agent,
was considered to be a useful tool.
The need for longer and more pro-active post-discharge
surveillance of surgical patients was also agreed to be a pri-
ority, especially given the current growth of day-case sur-
gery. It is clear that SSIs are currently under-reported but
initiatives will only be fully funded when accurate data
about the incidence, cost and causes of SSI are available.
The introduction of surgical safety checklists, such as the
World Health Organization’s Safe Surgery Saves Lives initia-
tive, is a useful contribution to improving safety and pre-
vention of SSIs and should be used universally. Further
refinement of checklist items pertinent to SSI should be
encouraged.
Considering sutures as ‘implants’, with a hard or non-shed-
ding surface to which micro-organisms can form biofilm and
cause SSIs, was felt to be a useful concept. Coating sutures with
an antimicrobial such as triclosan provides an effective strategy
for reducing SSIs. The panel commented that further ran-
domised controlled trials in a wider range of surgery are
required, with cost-benefit analyses of outcomes.
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